Management of cardiac arrhythmias and conduction disorders
... who are possible candidates for ICD therapy should undergo reevaluation of LVEF 40 or more days after discharge. (Level of Evidence: B) ...
... who are possible candidates for ICD therapy should undergo reevaluation of LVEF 40 or more days after discharge. (Level of Evidence: B) ...
Slide ()
... Schematic representation of the heart and normal cardiac electrical activity (intracellular recordings from areas indicated and ECG). Sinoatrial (SA) node, atrioventricular (AV) node, and Purkinje cells display pacemaker activity (phase 4 depolarization). The ECG is the body surface manifestation of ...
... Schematic representation of the heart and normal cardiac electrical activity (intracellular recordings from areas indicated and ECG). Sinoatrial (SA) node, atrioventricular (AV) node, and Purkinje cells display pacemaker activity (phase 4 depolarization). The ECG is the body surface manifestation of ...
Atrial Flutter
... Definition: Well-organised but overly rapid contractions of the atrium of the heart ...
... Definition: Well-organised but overly rapid contractions of the atrium of the heart ...
CRT +/
... Women have better heart-failure survival than men MAGGIC study Women with heart failure have better survival than man, irrespective of age, etiology and EF (patient data from 31 studies in 41 949 patients ). ...
... Women have better heart-failure survival than men MAGGIC study Women with heart failure have better survival than man, irrespective of age, etiology and EF (patient data from 31 studies in 41 949 patients ). ...
CRT +/
... Women have better heart-failure survival than men MAGGIC study Women with heart failure have better survival than man, irrespective of age, etiology and EF (patient data from 31 studies in 41 949 patients ). ...
... Women have better heart-failure survival than men MAGGIC study Women with heart failure have better survival than man, irrespective of age, etiology and EF (patient data from 31 studies in 41 949 patients ). ...
backgrounder
... Cardiac resynchronization therapy (CRT) is a treatment for heart failure that uses an implantable device to improve the pumping efficiency of the heart. In healthy people, the four chambers of the heart contract in synchrony to move blood through the body (people experience this as their heartbeat). ...
... Cardiac resynchronization therapy (CRT) is a treatment for heart failure that uses an implantable device to improve the pumping efficiency of the heart. In healthy people, the four chambers of the heart contract in synchrony to move blood through the body (people experience this as their heartbeat). ...
Levosimendan - Wellington ICU
... flow and renal blood flow. - increases: Q, SV, HR and increases coronary blood flow. - decreases: SVR, SBP, PCWP, PAP, coronary vascular resistance, myocardial oxygen consumption. - shown to improve symptoms, and BNP in cardiac failure (but, unfortunately not survival) - can be used with beta-blocke ...
... flow and renal blood flow. - increases: Q, SV, HR and increases coronary blood flow. - decreases: SVR, SBP, PCWP, PAP, coronary vascular resistance, myocardial oxygen consumption. - shown to improve symptoms, and BNP in cardiac failure (but, unfortunately not survival) - can be used with beta-blocke ...
Heart Failure: Dx and Management
... The incidence of HF approaches 10 per 1000 population after age 65 HF is the most common Medicare diagnosis-related group More dollars are spent for the diagnosis and treatment of HF than any other diagnosis by Medicare ...
... The incidence of HF approaches 10 per 1000 population after age 65 HF is the most common Medicare diagnosis-related group More dollars are spent for the diagnosis and treatment of HF than any other diagnosis by Medicare ...
Hospital X Is Among First Hospitals in U
... Technology to Improve Patient Quality of Life Physicians at [institution] are among the first to treat patients who suffer from irregular heartbeats with the most advanced implantable cardiac rhythm device technology. Medtronic’s new Protecta™ family of implantable cardioverterdefibrillators (ICDs) ...
... Technology to Improve Patient Quality of Life Physicians at [institution] are among the first to treat patients who suffer from irregular heartbeats with the most advanced implantable cardiac rhythm device technology. Medtronic’s new Protecta™ family of implantable cardioverterdefibrillators (ICDs) ...
EE 4BD4 Lecture 21 - McMaster University
... • Power supply: lithium type (iodide) long life 5 -10 years (early batteries 2 years max) • Oscillator: (fixed rate) set at 70 – 90 beats/min • Output circuit: Constant voltage 5.0 to 5.5, 500 – 600 µs duration; constant current 8 – 10 mA, 1.0 – 1.2 ms • Lead wires: inter-wound helical coils spring- ...
... • Power supply: lithium type (iodide) long life 5 -10 years (early batteries 2 years max) • Oscillator: (fixed rate) set at 70 – 90 beats/min • Output circuit: Constant voltage 5.0 to 5.5, 500 – 600 µs duration; constant current 8 – 10 mA, 1.0 – 1.2 ms • Lead wires: inter-wound helical coils spring- ...
Verification of Guidelines-Adherent Medical Therapy in Patients with
... Background. Hospitalization of patients with heart failure (HF) is a good opportunity to reevaluate patient care including optimizing present and planning future management. The aim of our study was to analyze medical management in patients with sinus rhythm hospitalized due to worsening of HF, who ...
... Background. Hospitalization of patients with heart failure (HF) is a good opportunity to reevaluate patient care including optimizing present and planning future management. The aim of our study was to analyze medical management in patients with sinus rhythm hospitalized due to worsening of HF, who ...
Left Ventricular Assist Devices: A Primer
... • Assists the left ventricle in passing oxygenated blood through the body. • Initially was a pulsatile device (similar to native heart…) ...
... • Assists the left ventricle in passing oxygenated blood through the body. • Initially was a pulsatile device (similar to native heart…) ...
Identifying Patients at High Risk for Sudden Cardiac Arrest in Your
... LVEF ≤ 35% and NYHA Functional Class II or III and On chronic optimal medical therapy Patient does not have any of the following contraindications*: NYHA Class IV (unless eligible for CRT) or Cardiogenic shock or hypotension or CABG or PTCA within past 3 months or Candidate for coronar ...
... LVEF ≤ 35% and NYHA Functional Class II or III and On chronic optimal medical therapy Patient does not have any of the following contraindications*: NYHA Class IV (unless eligible for CRT) or Cardiogenic shock or hypotension or CABG or PTCA within past 3 months or Candidate for coronar ...
Atrial Fibrillation as A Complication of Congestive Heart Failure in
... Heart failure (HF) is a clinical syndrome that present when the heart is unable to pump blood forward at a sufficient rate to meet the metabolic demands of the body. HF results in a clinical syndrome of dyspnea, fatigue, peripheral edema and rales. In CHF patient often occurs ventricular remodeling ...
... Heart failure (HF) is a clinical syndrome that present when the heart is unable to pump blood forward at a sufficient rate to meet the metabolic demands of the body. HF results in a clinical syndrome of dyspnea, fatigue, peripheral edema and rales. In CHF patient often occurs ventricular remodeling ...
Ventricular rate profiles during atrial fibrillation in heart failure patients
... CRT & monitoring: is it helpful? AF monitoring is important in patients with a CRT device because AF-induced high ventricular rate (VR) may cause loss of CRT ...
... CRT & monitoring: is it helpful? AF monitoring is important in patients with a CRT device because AF-induced high ventricular rate (VR) may cause loss of CRT ...
Intervention for congenital and structural heart disease: Beyond the
... pulmonary regurgitation in native outflow tracts. The aim of this strategy would be to prolong life expectancy and preserve normal right ventricular function by intervention before irreversible right ventricular electro-mechanical dysfunction sets in. However, as the authors point out, the outcome o ...
... pulmonary regurgitation in native outflow tracts. The aim of this strategy would be to prolong life expectancy and preserve normal right ventricular function by intervention before irreversible right ventricular electro-mechanical dysfunction sets in. However, as the authors point out, the outcome o ...
Slide 1 - AccessCardiology
... The pathophysiology of heart failure with preserved ejection fraction (HFpEF) is complex and highly interrelated, involving abnormalities in left ventricular (LV) systolic and diastolic reserve, arterial stiffening, endothelial dysfunction, chronotropic incompetence manifest by decreased heart rate ...
... The pathophysiology of heart failure with preserved ejection fraction (HFpEF) is complex and highly interrelated, involving abnormalities in left ventricular (LV) systolic and diastolic reserve, arterial stiffening, endothelial dysfunction, chronotropic incompetence manifest by decreased heart rate ...
Community Heart Failure Nurse Referral Form
... Class II: patients with slight, mild limitation of activity; they are comfortable with rest or with mild exertion. Class III: patients with marked limitation of activity; even during less-than-ordinary activity, comfortable only at rest. Class IV: patients who should be at complete rest, confined to ...
... Class II: patients with slight, mild limitation of activity; they are comfortable with rest or with mild exertion. Class III: patients with marked limitation of activity; even during less-than-ordinary activity, comfortable only at rest. Class IV: patients who should be at complete rest, confined to ...
10 Measures To Prevent Sudden Cardiac Death (SCD)
... Smoking cessation intervention in patients who suffered sudden cardiac arrest, have a life-threatening ventricular arrhythmia, or are at risk for SCD Screening for family history of SCD Screening for asymptomatic left ventricular dysfunction among individuals who have a strong family history of card ...
... Smoking cessation intervention in patients who suffered sudden cardiac arrest, have a life-threatening ventricular arrhythmia, or are at risk for SCD Screening for family history of SCD Screening for asymptomatic left ventricular dysfunction among individuals who have a strong family history of card ...
The Heart Continued
... changes in electrical potential across the heart – detects the contraction pulses that pass over the surface of the heart. – ECGs are useful in diagnosing heart abnormalities. ...
... changes in electrical potential across the heart – detects the contraction pulses that pass over the surface of the heart. – ECGs are useful in diagnosing heart abnormalities. ...
Placement of a left ventricular assist device in a patient with
... pulmonary arterial system. Oxygenated blood returns to the left atrium, passes through the morphologic tricuspid valve, into the right ventricle which then pumps systemically to the aorta. More than 2/3 of ccTGA patients also have associated cardiac anomalies such as VSD, which dictate the natural h ...
... pulmonary arterial system. Oxygenated blood returns to the left atrium, passes through the morphologic tricuspid valve, into the right ventricle which then pumps systemically to the aorta. More than 2/3 of ccTGA patients also have associated cardiac anomalies such as VSD, which dictate the natural h ...
Chapter_20_Heart_Review
... 1. Endocardium, myocardium, epicardium, and pericardium 2. Cardiac tamponade – aurocolloid 3. Left ventricle has the thickest wall due to work load 4. Chambers of the heart, atria and ventricle 5. Heart separations – septums and conary sulcus 6. Cardiac circulation – coronary artery and coronary sin ...
... 1. Endocardium, myocardium, epicardium, and pericardium 2. Cardiac tamponade – aurocolloid 3. Left ventricle has the thickest wall due to work load 4. Chambers of the heart, atria and ventricle 5. Heart separations – septums and conary sulcus 6. Cardiac circulation – coronary artery and coronary sin ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.